Evidence map›Paper›PMID 38605332›Full record

ArticleBMC cancer2024

Plasma extracellular vesicles in meningioma patients following radiotherapy as liquid biopsy- a prospective explorative biomarker study (ARO 2023-05/AG-NRO-07).

Maximilian Y Deng, Amanda Salviano da Silva, Pauline Carlotta Göller, Laila König, Henning Schäfer, Cecile Maire, Adriane Lentz-Hommertgen, Thomas Held, Sebastian Regnery, Tanja Eichkorn and 12 more

Abstract read
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Extracellular vesicles in spine tumors: biological roles, immune modulation, and therapeutic implications.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Maximilian Y DengDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany. Maximilian.deng@med.uni-heidelberg.de.
Amanda Salviano da SilvaDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Pauline Carlotta GöllerDepartment of Neuropathology, CCU Neuropathology, Heidelberg University Hospital, Heidelberg University, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Laila KönigDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Henning SchäferDepartment of Radiation Oncology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Cecile MaireDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Adriane Lentz-HommertgenDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Thomas HeldDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Sebastian RegneryDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Tanja EichkornDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Florian StritzkeDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Lukas BauerDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Daniel SchnellDepartment of Radiation Oncology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Klaus HerfarthDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Andreas von DeimlingDepartment of Neuropathology, CCU Neuropathology, Heidelberg University Hospital, Heidelberg University, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sandro KriegDepartment of Neurosurgery, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.
Antje WickNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.
Wolfgang WickNational Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.
Anca GrosuDepartment of Radiation Oncology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Jürgen DebusDepartment of Radiation Oncology, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.
Felix SahmDepartment of Neuropathology, CCU Neuropathology, Heidelberg University Hospital, Heidelberg University, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Franz RicklefsDepartment of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile surgical resection remains the primary treatment approach for symptomatic or growing meningiomas, radiotherapy represents an auspicious alternative in patients with meningiomas not safely amenable to surgery. Biopsies are often omitted in light of potential postoperative neurological deficits, resulting in a lack of histological grading and (molecular) risk stratification. In this prospective explorative biomarker study, extracellular vesicles in the bloodstream will be investigated in patients with macroscopic meningiomas to identify a biomarker for molecular risk stratification and disease monitoring.

methodsIn total, 60 patients with meningiomas and an indication of radiotherapy (RT) and macroscopic tumor on the planning MRI will be enrolled. Blood samples will be obtained before the start, during, and after radiotherapy, as well as during clinical follow-up every 6 months. Extracellular vesicles will be isolated from the blood samples, quantified and correlated with the clinical treatment response or progression. Further, nanopore sequencing-based DNA methylation profiles of plasma EV-DNA will be generated for methylation-based meningioma classification. DISCUSSION: This study will explore the dynamic of plasma EVs in meningioma patients under/after radiotherapy, with the objective of identifying potential biomarkers of (early) tumor progression. DNA methylation profiling of plasma EVs in meningioma patients may enable molecular risk stratification, facilitating a molecularly-guided target volume delineation and adjusted dose prescription during RT treatment planning.

Indexed as

Extracellular VesiclesMeningeal NeoplasmsMeningiomaBiomarkersHumansLiquid BiopsyProspective StudiesBiomarkersExtracellular vesiclesLiquid biopsyMeningioma.Radiotherapy

Identifiers

PMID38605332
PMCPMC11007956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.